Healthcare Resource Use and Economic Burden of B-Cell Acute Lymphoblastic Leukemia for Patients in the United States (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-221; Location: LEVEL 3, HALL B3; "Exclusions were pre-index B-ALL therapy, clinical trial participation, hospice, refractory or relapsed B-ALL, other B-cell malignancies or acute myeloid leukaemia, and daratumumab or nelarabine at baseline...Therapy included chemotherapy/rituximab (88.1%), TKIs (35.2%), blinatumomab (18.0%), inotuzumab (4.6%), and CAR-T (0.23%)... Adult US-based patients with B-ALL experience substantial and sustained economic burden following treatment initiation, with higher HCRU and costs driven primarily by medication, particularly advanced targeted therapies. Quantified, medication-driven costs following initiation give payers and providers actionable inputs for budget forecasting, and establish benchmarks to support value assessments for advanced therapies. Future research should stratify by treatment line and clinical risk, incorporate episode-based cost attribution, and include outcomes-adjusted evaluations to inform value."
Clinical • HEOR • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Neil D Palmisiano MD,MS 1; Yazan K Barqawi PharmD,PhD,MS,MBA 2; Julia Ma MS 3; Debbie Adkins MS PhD 4; Jesica M Levingston Mac Leod PhD 5; Jenny Lam MS PhD 2
|